Beacon Investment Advisory Services Inc. Has $26 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Beacon Investment Advisory Services Inc. increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 0.2% in the 4th quarter, HoldingsChannel.com reports. The firm owned 302,233 shares of the company’s stock after acquiring an additional 641 shares during the period. Beacon Investment Advisory Services Inc.’s holdings in Novo Nordisk A/S were worth $25,998,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in NVO. Natixis Advisors LLC grew its position in shares of Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after acquiring an additional 80,070 shares during the period. Norman Fields Gottscho Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 45.3% during the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after buying an additional 19,870 shares in the last quarter. Talbot Financial LLC bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $4,066,000. Versant Capital Management Inc acquired a new position in shares of Novo Nordisk A/S in the fourth quarter valued at about $86,000. Finally, Zions Bancorporation N.A. increased its position in Novo Nordisk A/S by 57.0% during the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after acquiring an additional 6,726 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 0.5 %

NVO opened at $80.59 on Thursday. The stock has a market cap of $361.65 billion, a PE ratio of 26.08, a price-to-earnings-growth ratio of 0.89 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15. The company has a fifty day moving average of $96.10 and a 200-day moving average of $115.79.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on NVO shares. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.